STEMI; mRNA vaccine-associated myocarditis; This literature-non-study case was reported in a literature article and describes the occurrence of ACUTE MYOCARDIAL INFARCTION (STEMI) and MYOCARDITIS (mRNA vaccine-associated myocarditis) in a 48-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.   The patient's past medical history included Viral myocarditis (Patient had a history of previous viral myocarditis seven years ago).  On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced ACUTE MYOCARDIAL INFARCTION (STEMI) (seriousness criterion medically significant) and MYOCARDITIS (mRNA vaccine-associated myocarditis) (seriousness criterion medically significant). At the time of the report, ACUTE MYOCARDIAL INFARCTION (STEMI) and MYOCARDITIS (mRNA vaccine-associated myocarditis) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood test: improvement Improvement in serum markers was observed. On an unknown date, Catheterisation cardiac: normal coronaries (normal) Emergent left heart catheterization had revealed normal coronaries. On an unknown date, Electrocardiogram: stemi EKG findings had revealed STEMI shortly after receiving the second dose.   For mRNA-1273 (Spikevax) (Unknown), the reporter considered ACUTE MYOCARDIAL INFARCTION (STEMI) and MYOCARDITIS (mRNA vaccine-associated myocarditis) to be related.    Concomitant and treatment medications were not reported.   The authors stated that it remains unclear if the patient's history of previous viral myocarditis could be a predisposing factor to the development of mRNA vaccine-associated myocarditis.  Company Comment: This literature-non-study case concerns a 48-year-old, male patient with medical history of Viral Myocarditis (7 years ago), who experienced the unexpected, serious (medically significant) AESI of acute myocardial infarction and the expected, serious (medically significant) AESI of myocarditis after receiving the second dose of the mRNA-1273 vaccine on an unspecified date. The start dates of the events were not provided. The patient presented with chest pain and Electrocardiogram findings of ST-elevation myocardial infarction (STEMI). Emergent left heart catheterization was done which revealed normal coronaries. Subsequently, the patient had rapid resolution of symptoms and improvement in serum markers (unspecified). Treatment information was not provided. The medical history of Viral Myocarditis remains a confounder. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Further information has been requested.; Sender's Comments: This literature-non-study case concerns a 48-year-old, male patient with medical history of Viral Myocarditis (7 years ago), who experienced the unexpected, serious (medically significant) AESI of acute myocardial infarction and the expected, serious (medically significant) AESI of myocarditis after receiving the second dose of the mRNA-1273 vaccine on an unspecified date. The start dates of the events were not provided. The patient presented with chest pain and Electrocardiogram findings of ST-elevation myocardial infarction (STEMI). Emergent left heart catheterization was done which revealed normal coronaries. Subsequently, the patient had rapid resolution of symptoms and improvement in serum markers (unspecified). Treatment information was not provided. The medical history of Viral Myocarditis remains a confounder. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Further information has been requested.